Literature DB >> 27775794

Fibroblast growth factor 23 serum level in type 2 diabetic italian subjects with peripheral arterial disease and critical limb ischemia.

F Biscetti1, G Straface, D Pitocco, F Angelini, G Tinelli, R Landolfi, A Flex.   

Abstract

OBJECTIVE: Fibroblast growth factor 23 (FGF23) was demonstrated to be involved in the occurrence and development of cardiovascular disease (CVD). The aim of this study was to investigate the potential role of FGF23 on presence and severity of peripheral arterial disease (PAD) in type 2 diabetic patients. PATIENTS AND METHODS: In this study, we analyzed FGF23 serum levels in 413 type 2 diabetic patients with PAD and in 598 diabetic controls without lower limbs atherosclerosis.
RESULTS: We found that FGF23 median serum levels were significantly higher in patients than in diabetic controls (69.3 (58.8-75.1) pg/mL in PAD and 42.98 (37.1-49.8) pg/mL in subjects without PAD (p < 0.001) and were significantly and independently associated with critical limb ischemia (CLI) [OR, 7.69 (2.64-16.31); p = 0.001].
CONCLUSIONS: We have found, for the first time, that FGF23 could be associated with presence and severity of PAD in Italian patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27775794

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

Review 1.  Biomarkers of vascular disease in diabetes: the adipose-immune system cross talk.

Authors:  Federico Biscetti; Elisabetta Nardella; Andrea Leonardo Cecchini; Andrea Flex; Raffaele Landolfi
Journal:  Intern Emerg Med       Date:  2020-01-09       Impact factor: 3.397

2.  Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects.

Authors:  Silvia Giovannini; Giovanni Tinelli; Federico Biscetti; Giuseppe Straface; Flavia Angelini; Dario Pitocco; Luciana Mucci; Raffaele Landolfi; Andrea Flex
Journal:  Cardiovasc Diabetol       Date:  2017-08-08       Impact factor: 9.951

3.  Elevated serum fibroblast growth factor 23 levels as an indicator of lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus.

Authors:  Xingxing He; Xiang Hu; Xiaojing Ma; Hang Su; Lingwen Ying; Jiahui Peng; Xiaoping Pan; Yuqian Bao; Jian Zhou; Weiping Jia
Journal:  Cardiovasc Diabetol       Date:  2017-06-15       Impact factor: 9.951

Review 4.  High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives.

Authors:  Federico Biscetti; Maria Margherita Rando; Elisabetta Nardella; Andrea Leonardo Cecchini; Giovanni Pecorini; Raffaele Landolfi; Andrea Flex
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

5.  Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study.

Authors:  Federico Biscetti; Elisabetta Nardella; Maria Margherita Rando; Andrea Leonardo Cecchini; Flavia Angelini; Alessandro Cina; Roberto Iezzi; Marco Filipponi; Angelo Santoliquido; Dario Pitocco; Raffaele Landolfi; Andrea Flex
Journal:  Cardiovasc Diabetol       Date:  2020-10-07       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.